This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Nagar, B. et al. Cancer Res. 62, 4236–4243 (2002).
O'Hare, T. et al. Blood 104, 2532–2539 (2004).
Seggewiss, R. et al. Blood 105, 2473–2479 (2005).
O'Hare, T., Walters, D.K., Deininger, M.W. & Druker, B.J. Cancer Cell 7, 117–119 (2005).
Weisberg, E. et al. Cancer Cell 7, 129–141 (2005).
Shah, N.P. et al. Science 305, 399–401 (2004).
O'Hare, T. et al. Cancer Res. 65, 4500–4505 (2005).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
O'Hare, T., Druker, B. BIRB-796 is not an effective ABL(T315I) inhibitor. Nat Biotechnol 23, 1209–1210 (2005). https://doi.org/10.1038/nbt1005-1209
Issue Date:
DOI: https://doi.org/10.1038/nbt1005-1209
This article is cited by
-
Flying under the radar: the new wave of BCR–ABL inhibitors
Nature Reviews Drug Discovery (2007)
-
The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias
International Journal of Clinical Oncology (2007)
-
Response to Molecule–kinase interaction map
Nature Biotechnology (2005)